14.06.2016 • News

Carbogen Amcis Expanding Swiss Capacity

(c) Westend61/Getty Images
(c) Westend61/Getty Images

Carbogen Amcis, a Swiss company specialized in process development and manufacturing of Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is expanding its   operations in Bubendorf, Switzerland, to take account of a “significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small scale development.”

The company has purchased a 3,360 m2 multi-story building on 5,200 m² of land and will convert it to its own specifications. When operations begin in January 2017, the premises will house laboratory, production, storage and office areas and provide a set of clean-room GMP compliant suites.

Stephan Fritschi, vice president Operations at Carbogen Amcis, said the immediate proximity to the company’s current headquarters and its larger scale production site in Bubendorf, Switzerland, is “ideal,” as it will allow a significantly expansion of laboratory capacity for highly potent development and small scale production as well as analytical support.

In the near future, the company said it plans to introduce a number of additional capabilities including commercial manufacture of ADCs and additional Cat 4 (ng OEL) development capacity.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.